Description: MiMedx Group, Inc. is an advanced wound care and an emerging therapeutic biologics company. It engages in developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The company processes the human placental tissue utilizing its proprietary PURION process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx Group was founded on July 30, 1985 and is headquartered in Marietta, GA
Home Page: www.mimedx.com
MDXG Technical Analysis
1775 West Oak Commons Court, NE
Marietta,
GA
30062
United States
Phone:
770 651 9100
Officers
| Name | Title |
|---|---|
| Mr. K. Todd Newton | Interim CEO & Director |
| Mr. Peter Martin Carlson CPA | Chief Financial Officer |
| Mr. William F. Hulse IV | Gen. Counsel & Chief Admin. Officer |
| Dr. Rohit Kashyap Ph.D. | Pres of Wound Care & Surgical |
| Dr. Robert Benjamin Stein M.D., Ph.D. | Pres of Regenerative Medicine & Biologics Innovation |
| Mr. Scott M. Turner | Sr. VP of Operations & Procurement |
| Mr. William L. Phelan | Sr. VP & Chief Accounting Officer |
| Mr. Matthew M. Notarianni | Head of Investor Relations |
| Mr. Mark P. Graves | Sr. VP & Chief Compliance Officer |
| Hilary Dixon | VP of Investor Relations & Corp. Strategic Communications |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 82.486 |
| Price-to-Sales TTM: | 1.2984 |
| IPO Date: | 2007-08-22 |
| Fiscal Year End: | December |
| Full Time Employees: | 811 |